Cost-effectiveness analysis of aprepitant-based anti-emetic regimen for children receiving highly emetogenic chemotherapy: Individual patient data analysis of a randomized trial.

Manraj Singh SraShuvadeep GangulyArchana SasiPriya SharmaRupak Kumar GiriAzgar Abdul RasheedSameer Bakhshi

Published in: Pediatric blood & cancer (2022)

Aprepitant-based anti-emetic regimen is cost-effective for children receiving HEC. It results in overall cost savings and reduced healthcare-resource utilization.

Keyphrases

chemotherapy induced
healthcare
young adults
case report
electronic health record
squamous cell carcinoma
machine learning
locally advanced
deep learning
health information